Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbial transplantation
- Development stage
- Unknown
- Lead developer
- Ella Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Fecal Microbial Transplantation (FMT) by Ella Therapeutics is a live biotherapeutic product consisting of fecal microbiota derived from healthy donors. It is designed to modulate the gut microbiome ecosystem to overcome resistance to immune checkpoint inhibitors, specifically anti-PD-1 therapies like nivolumab. The therapy aims to restore a favorable microbial environment that promotes systemic immune activation. It is currently being investigated in a Phase Ib clinical trial for patients with metastatic or inoperable melanoma, non-small cell lung cancer (NSCLC), and microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) solid tumors who are refractory to prior immunotherapy.
- Other names
- FMTFecal Microbiota Transplantation
Beyond the preview
Go deeper on fecal microbial transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbial transplantation.